SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-055613
Filing Date
2021-04-27
Accepted
2021-04-27 16:15:36
Documents
4
Period of Report
2021-06-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm212663-1_def14a.htm DEF 14A 571643
2 GRAPHIC lg_akerotherepeatics-4c.jpg GRAPHIC 34539
3 GRAPHIC tm212663d1-proxy_1akerobw.jpg GRAPHIC 561781
4 GRAPHIC tm212663d1-proxy_2akerobw.jpg GRAPHIC 432400
  Complete submission text file 0001104659-21-055613.txt   1988875
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38944 | Film No.: 21859087
SIC: 2834 Pharmaceutical Preparations